Furthermore, anti-angiogenic therapies, which block VEGF signaling in tumor blood vessels, exacerbate tumor hypoxia, a condition of low oxygen levels that upregulates MET and activates MET-dependent invasive growth in cancer cells [169]. This evidence concerns the gene MET and cancer.